2,669 reports of this reaction
2.3% of all LEVETIRACETAM IN SODIUM CHLORIDE reports
#5 most reported adverse reaction
EPILEPSY is the #5 most commonly reported adverse reaction for LEVETIRACETAM IN SODIUM CHLORIDE, manufactured by Actavis Pharma, Inc.. There are 2,669 FDA adverse event reports linking LEVETIRACETAM IN SODIUM CHLORIDE to EPILEPSY. This represents approximately 2.3% of all 117,343 adverse event reports for this drug.
Patients taking LEVETIRACETAM IN SODIUM CHLORIDE who experience epilepsy should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
EPILEPSY is a less commonly reported adverse event for LEVETIRACETAM IN SODIUM CHLORIDE, but still significant enough to appear in the safety profile.
In addition to epilepsy, the following adverse reactions have been reported for LEVETIRACETAM IN SODIUM CHLORIDE:
The following drugs have also been linked to epilepsy in FDA adverse event reports:
EPILEPSY has been reported as an adverse event in 2,669 FDA reports for LEVETIRACETAM IN SODIUM CHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
EPILEPSY accounts for approximately 2.3% of all adverse event reports for LEVETIRACETAM IN SODIUM CHLORIDE, making it a notable side effect.
If you experience epilepsy while taking LEVETIRACETAM IN SODIUM CHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.